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Analysis of a subset of case-control sporadic breast cancer data,
[from the National Cancer Institute’s Cancer Genetic Markers of
Susceptibility (CGEMS) initiative], focusing on 18 breast cancer-
related genes with 304 SNPs, indicates that there are many inter-
esting interactions that form two- and three-way networks in
which BRCA1 plays a dominant and central role. The apparent
interactions of BRCA1 with many other genes suggests the con-
jecture that BRCA1 serves as a protective gene and that some
mutations in it or in related genes may prevent it from carrying out
this protective function even if the patients are not carriers of
known cancer-predisposing BRCA1mutations. The method of anal-
ysis features the evaluation of the effect of a gene by averaging the
effects of the SNPs covered by that gene. Marginal methods that
test one gene at a time fail to show any effect. That may be related
to the fact that each of these 18 genes adds very little to the risk
of cancer. Analysis that relates the ratio of interactions to the
maximum of the first-order effects discovers significant gene pairs
and triplets.
Breast cancer (MIM 114480) has complex causes. Knownpredisposition genes explain 15% of the breast cancer
cases. It is generally believed that most sporadic breast cancers
are triggered by unknown combined effects, possibly because of
a large number of genes and other risk factors, each adding a
small risk toward cancer etiology. Progress in seeking breast
cancer genes other than BRCA1 and BRCA2 has been slow and
limited because the individual risk due to each gene is small. This
difficulty may be partly due to the fact that current methods rely
largely on marginal information from genes studied one at a time
and ignore potentially valuable information because of the
interaction among multiple loci. Because each responsible gene
may have a small marginal effect in causing disease, it is likely
that such methods will fail to capture many responsible genes by
studying a dataset where the disease may be due to a variety of
different sources. The possible presence of many genes responsible
for different subgroups of cancer patients may reduce the power of
current methods to detect genes partly responsible for some forms
of breast cancer. It is believed that methods effective in extracting
interactive information from data should be developed.
What should be done when marginal effects are too weak to
be detected? Our methods use interactive information from
multiple sites as well as marginal information, They provide
power to detect interactive genes. To test this claim and to
demonstrate the practical value of these methods in real appli-
cations, we apply them to an important study: a subset of a large
dataset collected from a case-control sporadic breast cancer
study, focusing on gene–gene-based analysis. This partial dataset
comprises 18 genes with 304 SNP markers. The application
results in a number of scientific findings.
The message of this article is fourfold. First, if marginal
methods fail, more powerful methods that take into account
interactive information can be used effectively. We apply our
proposedmethods to this dataset to illustrate the detection of the
interactions between genes. We point out that in our findings,
none of the 18 selected genes show any detectable marginal
effects that are significantly higher than those generated by
random fluctuations. In other words, all of the 18 genes would
be missed if only marginal methods were used.
Second, we demonstrate how to carry out a gene-based
analysis by treating each gene as a basic unit while incorporating
relevant information from all SNPs within that gene. Two
summary test scores are proposed to quantify the strength of
interactions for each pair of genes. The pairwise interactions can
be extended easily. We also provide results using third-order
interactions.
Third, to establish statistical significance, we generate a large
number of permutations of the dependent variable (case or
control) to see how the measures of interaction for the real data
compare with those from the many permutations.
Finally, when these procedures are applied to the data, they
lead to a number of interesting findings. It is shown that there are
a substantial number of significant interactions that form a
network in which BRCA1 plays a dominant role. The interactions
of BRCA1 with many of the other genes suggests the conjecture
that BRCA1 serves as a protective gene and that some mutations
in it or in related genes may prevent it from carrying out the
protective function.
Results
None of the 18 marginal effects are significantly higher than
those generated by random permutations. This claim is made
based on comparisons between the observed 18 V values and the
values obtained from 1,000 permutations. The exact procedures
carried out were described in steps 1 and 2 in Methods. Of the
18 genes, the most significant one is BARD1 with a P value 
0.053, which is slightly short of being significant at 0.05. It is also
noticed that BRCA1 has a very large P value (0.944), meaning
that the real effects of BRCA1, as well as those of the other genes
in breast cancer, cannot be properly measured and reflected by
its marginal effect alone. It is the interactive effect that reveals
the roles of some of these genes in breast cancer. See supporting
information (SI) Fig. S1.
In seeking pairwise interactions among the 18 genes, both
Mean-ratio and Quantile-ratio methods were implemented.
Although the Mean-ratio method using (M, R) is more conser-
vative than the Quantile-ratio method using (M, Q), it still
identified 16 of 153 pairs as significant gene pairs at the 0.05 level
that are connected with breast cancer etiology with an estimated
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false discovery rate (FDR) of 50%. Of these 16 pairs, three pairs,
(BRCA1, ESR1), (BARD1, ESR1) and (BRCA1, KRAS2) are
significant even under more stringent criteria. The estimated P
values are 0.001, 0.003 and 0.004; see Table 1. Four pairs are
significant at level 0.01, and the remaining pairs are significant
at the 0.05 level by using the rank method. A pairwise network
based on these 16 pairs is shown in Fig. 1. On the other hand, the
Quantile-ratio method is more powerful. For example, 18 pairs
of genes with an estimated FDR of 40% were identified. A
pairwise network based on these 18 pairs is shown in Fig. 2. It
is interesting to note that 15 of the 18 identified pairs were also
found by the Mean-ratio method.
Using the gene database from the National Center for Biotech-
nology Information (NCBI), we compare our results with published
findings on these gene pairs. In Fig. 2, we have labeled with a red
dot the interactions that were previously biologically identified.
There have been multiple reports on the biochemical inter-
actions between BRCA1 and BARD1 (e.g., refs. 1 and 2). Meza
et al. (1) studied, in detail, their interaction regarding the
structure domains for the interaction, binding activities, etc.
Further studies have shown that a subset of mutations at BRCA1
can affect the BRCA1–BARD1 interaction’s relation with the
susceptibility to breast cancer (3).
Functional interaction between BRCA1 and RAD51 has been
identified and suggested to play a role during the S phase of the
cell cycle, which is of critical importance for genome integrity
(4). Levy-Lahad et al. (5) found evidence suggesting that a
mutation at RAD51 modified breast cancer risk among BRCA2
carriers but not BRCA1 carriers. It is interesting that we detected
interaction between the RAD51–BRCA1 genes among sporadic
breast cancer patients, whereas neither gene demonstrated
strong marginal effects.
CHEK2 is an important breast cancer candidate gene. Its
association with breast cancer has been widely studied in mul-
tiple populations (e.g., refs. 6- 8), and it has been shown to be a
low-penetrance breast cancer-susceptibility gene (9) and sug-
gested to have complex yet limited involvement in breast cancer
etiology (7, 10). Interestingly, as noted in ref. 10, the
CHEK2*1100delC mutation was observed more frequently
among cases with a first-degree-relative breast cancer patient.
This may suggest thatCHEK2may interact with important breast
cancer-susceptibility genes as a risk modifier. The BRCA1–
CHEK2 interaction is known to be important for DNA damage
response (10). Our findings suggested that the association be-
tween the BRCA1–CHEK2 interaction and breast cancer sus-
ceptibility is much stronger than themarginal effects of these two
Table 1. Significance of the gene pairs identified by the Mean-ratio and Quantile-ratio methods with P values estimated by the curve
and rank methods
Pair no.
Mean-ratio method Quantile-ratio method
Gene pair Curve P Rank P Gene pair Curve P Rank P
1 ESR1 BRCA1 0.017 0.001 ESR1 BRCA1 0.013 0.001
2 BRCA1 PHB 0.026 0.040 BRCA1 PHB 0.029 0.073
3 KRAS2 BRCA1 0.002 0.006 KRAS2 BRCA1 0.002 0.004
4 SLC22A18 BRCA1 0.032 0.072 SLC22A18 BRCA1 0.019 0.079
5 RAD51 BRCA1 0.052 0.090 RAD51 BRCA1 0.005 0.032
6 RB1CC1 SLC22A18 0.024 0.026 ESR1 SLC22A18 0.033 0.016
7 CASP8 KRAS2 0.043 0.038 RB1CC1 SLC22A18 0.009 0.008
8 CASP8 SLC22A18 0.042 0.048 CASP8 KRAS2 0.038 0.036
9 PIK3CA BRCA1 0.030 0.048 CASP8 SLC22A18 0.021 0.012
10 PIK3CA ESR1 0.047 0.032 PIK3CA BRCA1 0.014 0.049
11 PIK3CA RB1CC1 0.047 0.051 PIK3CA ESR1 0.021 0.005
12 PIK3CA SLC22A18 0.025 0.036 PIK3CA RB1CC1 0.044 0.053
13 BRCA1 CHEK2 0.016 0.031 CASP8 PIK3CA 0.007 0.009
14 BARD1 BRCA1 0.032 0.057 BRCA1 CHEK2 0.007 0.022
15 BARD1 ESR1 0.044 0.025 BARD1 BRCA1 0.003 0.015
16 BARD1 TP53 0.019 0.019 BARD1 ESR1 0.017 0.003
17 BARD1 TP53 0.015 0.010
18 BARD1 SLC22A18 0.056 0.063
CASP8 ESR1 0.071 0.048 CASP8 ESR1 0.066 0.031
BARD1 KRAS2 0.055 0.036
ESR1 KRAS2 0.145 0.001 ESR1 KRAS2 0.103 0.001
ESR1 PPM1D 0.252 0.021 ESR1 PPM1D 0.348 0.001
The gene pairs are listed in the same order as in Figs. 3 and 4.
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Fig. 1. Pairwise network based on 16 pairs of genes identified by the
Mean-ratio method.
Weaker 
 Interactio n 
Stronger 
 Interactio n 
Legend of Link  C olor 
 in Gene Networ k 
Fig. 2. Pairwise network based on 18 pairs of genes identified by the
Quantile-ratio method.
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genes. The involvement of this interaction in breast cancer, if
validated, might explain the seemingly weak relevance ofCHEK2
to breast cancer risk.
The relation between breast cancer and estrogen receptor-
(ER) deficiency has been one of the important research areas
in breast cancer research. Hosey et al. (11) studied the mRNA
expression levels of ESR1 in samples from BRCA1 breast cancer
patients and sporadic breast cancer patients and reported that
BRCA1 mutation reduces the activities of ESR1. Fan et al. (12)
suggested that the wild-type BRCA1 gene may inhibit the
transcriptional activities of the ER pathway. These two articles
indicated both the BRCA1 mutations and the wild-type alleles
are associated with reduced activities of the ER pathway under
specific conditions. This may suggest that some combinations of
genetic variations at the loci of BRCA1 and ESR1 are involved
in deciding the risk of breast cancer.
We found a very high correlation between the P values
obtained by the global permutation curve method and the P
values obtained by the alternative rank procedure. This is shown
in Figs. S2 and S3., Among the 16 pairs of genes identified by
using the curve method on the ratios or (M, R), 12 have P
values  0.05 by the rank method. Among the 18 pairs of gene
pairs identified by using the curvemethod on the quantiles or (M,
Q), 14 are with P values  0.05 by the alternative rank method.
See Table 1 for details.
If we were to use the rank method on the quantiles with a
cut-off threshold of 0.016, there would be 12 pairs that appear
significant, whereas only 2.45 would be expected by chance. This
corresponds to an estimated FDR of 20%.
For three-way interactions, setting the curve at 99.5%, we
report the following findings. From Fig. S4, the ratio method
identified 10 of 814 gene triplets to be significantly connected
with breast cancer etiology with an estimated FDR of 40%. From
Fig. S5, the quantile method with q  0.90 identified eight of
them, with an estimated FDR of 50%. Three triplets are
identified by both the ratio and quantile methods. One triplet
(RAD51, TP53, BRCA1) is strongly significant under a stringent
criteria (the estimated all-triplets-wide significance is  0.005),
and the rest of triplets are potentially significant. A three-way
interaction network based on the 10 triplets identified by the
ratio method is shown in Fig. S6. A three-way interaction
network identified by the quantile method is shown in Fig. S7.
Discussion
The application of our methods on sporadic breast cancer data
reveals evidence of numerous interactions among 18 genes
previously identified in the literature to be relevant to breast
cancer. It is shown that BRCA1 interacts with many of these
genes and suggests the conjecture that BRCA1 participates in
various tumor-suppression activities and that mutations in
BRCA1 or in one of these other interacting genes interferes with
these cancer-prevention activities. Biological studies will prob-
ably be required to investigate this conjecture. Until recently,
there have been a few studies of interactions using a single gene
as a unit. For example, Chatterjee et al. (13) and Chapman and
Clayton (14) proposed approaches for modeling gene–gene
interaction using SNPs within the genes, which may be applied
for the analysis of a small number of candidate gene pairs.
Specifically, their approaches can be applied to the findings of
this article by using independent data.
Our data involved many SNPs even when we restricted
ourselves to only 18 genes and the 304 SNPs in the neighborhood
of these genes. Because it seemed very unlikely that a mutation
in any of those SNPs would be directly causal, it mademore sense
to average the effects of the SNPs in the neighborhood of the
gene and to do the resulting analysis on a gene basis. Because
these data revealed no signs of marginal effects of individual
genes, analysis was carried out on pairs of genes. Although the
pairs by themselves did not show signs of strong effect, the
differences between the pairwise and marginal effects led to
the study of the mean and quantile ratios. Each of these, when
combined with themean of themaximum of themarginal effects,
indicated a significant effect when compared with results ob-
tained by permutations. We suggest that breast cancer data
already collected could be reanalyzed by the methods of this
article and that such reanalysis might lead to interesting findings.
Materials and Methods
Breast Cancer Data. The Cancer Genetic Markers of Susceptibility (CGEMS)
(http://cgems.cancer.gov/data/) is an initiative from the National Cancer Institute
(NCI) searchingfor susceptibilitygenetic loci forbreast cancerandprostatecancer
on the whole-genome scale (15). We received, from CGEMS, the breast cancer
data on 2,287 postmenopausal women from the Nurses’ Health Study (NHS).
Among these individuals, 1,145 developed breast cancer during the observation
period of the study, and the other 1,142 did not. By using the Illumina 550k chip,
these individuals were genotyped on 550,000 SNPs. In this article, instead of
carrying out a genome-wide study of all of the markers in this dataset, we chose
to focus on a set of carefully selected candidate genes of breast cancer and study
their breast cancer-related interactions. To proceed, we first select 18 genes that
the literature has shown to be of relevance to breast cancer.
From CGEMS-NHS breast cancer data, we identified a total of 304 SNPs that
cover 18 genes that are believed to have connections with breast cancer. The
choice of these 18 genes, includingBRCA1andBRCA2, was guided by the publicly
available information reported in Online Mendelian Inheritance in Man (OMIM).
These genes are listed in Table 2 according to their order of location along the 23
chromosomes, along with the number of SNPs within each gene.
The reported relations between the selected genes and breast cancer is
now briefly reviewed. The CASP8 gene is included because of the association
between one of its variants and reduced risk of breast cancer (16). Breast
cancer susceptibility alleles have been reported in both the BARD1 gene (17)
and the CHEK2 gene (9). Somatic mutation in the PIK3CA gene was identified
in breast cancer (18). A single-gene amplification of the ESR1 gene is detected
among breast cancer patients, suggesting that ESR1 amplification is an early
genetic alteration in breast cancer development (19). Those genes for which
mutations, often at more than one locus, were found among breast cancer
cases or families include the RB1CC1 gene (20), the BRCA2 gene (21), the TP53
gene (22), the BRCA1 gene, and the BRIP1 gene (23). The wild-type TSG101 is
a tumor gene. Li et al. (24) suggested that defects in the gene TSG101 occur
during breast cancer tumorigenesis or progression. Gallagher et al. (25) report
that the gain of imprinting affects both the sense and the antisense transcripts
at the locus of the SLC22A18 gene. There is evidence that heterozygotes for
some mutations in the ATM gene have an increased risk of breast cancer (26).
KRAS is said to be one of the most activated oncogenes, with 17–25% of all
human tumors harboring an activating KRAS mutation (27). The PALB2 gene
encodes a BRCA2-interacting protein and has been shown to play a role in
familial breast cancer (28, 29). The PHB gene shows evidence of mutations
linked to sporadic breast cancer (30). The PPM1D gene is commonly amplified
in breast cancer and abrogates P53 tumor-suppressor activity (31).
Table 2. Breast cancer candidate genes studied
Gene Locus SNPs Gene Locus SNPs Gene Locus SNPs Gene Locus SNPs
CASP8 2q33-q34 12 TSG101 11p15 11 BRCA2 13q12.3 31 BRIP1 17q22-q24 19
BARD1 2q34-q35 27 SLC22A18 11p15.5 16 RAD51 15q15.1 4 PPM1D 17q23.2 2
PIK3CA 3q26.3 8 ATM 11q22-q23 12 TP53 17p13.1 6 CHEK2 22q12.1 11
ESR1 6q25.1 78 PALB2 16p12.1 7 BRCA1 17q21 13
RB1CC1 8q11 9 KRAS2 12p12.1 28 PHB 17q21 10












The number of SNPs of the region that covers the corresponding gene varies
from gene to gene, ranging from 2 to 78 SNPs. Because on average there are
3,000 bp between two consecutive SNPs, the largest region that covers the
correspondinggenemayspreadovermorethan100,000bp. It isalsonotedthat
the genotypes of nearby SNPs are dependent on each other (with a noticeable
linkage disequilibrium), and this dependence may stretch rather far along the
regions. To take advantage of this dependence and to integrate the neighboring
information, we treat each gene/region as a basic unit instead of treating each
SNPasaunit.This illustratesour ‘‘gene-basedapproach,’’ inwhich informationon
SNPs is combined into one unit for that gene. Therefore, when we talk about the
effect of a certain region or a certain gene, we simply mean the average effect of
all individual effects due to all of the SNPs within that region/gene. Analogously,
a two-way interaction of two genes. constitutes the average of all pairwise
interactions of SNP pairs formed from the two regions/genes, one from each.
Methods.Considerk SNPs in a case-control study. Because each SNP determines
three genotypes, k SNPs define 3k multilocus genotypes that form a partition
 of the dataset into corresponding subsets called partition elements. We
shall use the following genotype statistics to measure the observed joint effect
of these k SNPs on the disease status:
v 
s1
3k nD,snD  nU,snU 
2
, [1]
where nD,s and nU,s are counts of cases and controls in genotype (element) s,
nD, and nU are the total number of cases and controls under study. Let ns nD,s
 nU,s be the number of observations in genotype s.
Let Y be the disease status, 1 for cases and 0 for controls. Then, for a
genotype partition , the statistic v discussed in this article was used in our





2Y s Y 2. [2]
The key statistics used in this article are all derived from v.
We offer the following view of how two genetic loci can act jointly to affect
their disease outcome. If the joint effect exceeds their individual marginal
effect, we regard this as evidence of ‘‘interaction.’’ Specifically, our concept of
interaction of two loci at i and j is that vij is substantially greater than max(vi,
vj). The implication is that such an effect, in a large population, suggests that
there may be a causal mechanism of biological importance. In the rest of this
article, the joint effect of two loci is referred to as a second-order effect, and
the marginal effect of one locus is called a first-order effect.
First-order effects failed to indicate anything special about the 18 genes.
Second-order effects for pairs of genes were also very disappointing until we
compared the second-order effects with the first-order ones. The ratio of the
improvement, due to second order over the first order, seemed to signal some
connections. This indication was especially impressive when this ratio was
compared with the maximum of the two first-order effects in a two-
dimensional graph. Two alternative ratios, to be defined later, are considered
to be used in conjunction with the maximum of the first-order effects. These
will be called the Mean-ratio and Quantile-ratio.
To establish significance, we applied 1,000 permutations of the case-control
outcomes, to determine the null distribution of the ratio and the maximum
partially described above. We propose two methods of assigning significance
levels. One will be called the curve method and the other, the rank method.
Summary of Procedures. 1. Suppose that there are mi SNPs in gene i. For SNP
d of gene i we calculate vid (defined as in Eq. 1 for k 1) and take the average
over themi SNPs within the gene. This leads to 18 averagesV {V1,V2. . . ,V18},
each representing the (marginal/main) effect of one of the genes. We also
calculate the (pairwise/interaction) two-dimensional genotype statistics vid je,
defined as in Eq. 1 for k  2, for all (304  303)/2  46,056 SNP pairs.
Throughout the article, we will use the lowercase to denote the quantities at
the SNP-level and uppercase for the gene-level. Also, although we confine
ourselves here to SNPs on 18 genes, our methods would apply equally well to
a set of SNPs that cover a region of interest that is not necessarily a gene.
2. To detect possible causal effects of genes on disease status, we should
know what to expect if there is no relationship. To obtain this information, we
destroy any relationship by means of a random permutation of the labels of
case (Y  1) and control (Y  0) and carry out the step 1 above with the
permuted data. For example, calculations based on the first part of step 1
generate 304 random effects (values) purely by chance, whereas the original
dependence among SNPs in each gene is retained. We repeat this procedure
1,000 times to produce 1,000 sets of 304 values denoted by v(p)  {vid
(p), 1 i
304}, where {1 p 1,000}. Similarly, one can estimate the null distribution of v
for a pair of SNPs when there is no relationship by using the permuted data 1,000
timesfollowingthesecondpartofstep1. Inthisarticleweuse1,000permutations
for two-way interactions but only 100 for three-way interactions.
For the benefit of nonstatisticians reading this paper, we digress to present
a tutorial on significance levels because of the somewhat unusual applications
we face in this presentation. The method of significance testing has had an
important history in science. A scientist, who is interested in whether his data
represent the presence of an effect of interest or are due to random fluctu-
ations, formulates a null hypothesis that there is no effect. He calculates a
statistic, T, based on the data. He finds the probability distribution of T,
assuming the null hypothesis. He then calculates a P value that is the proba-
bility, under the null hypothesis, that T exceeds the observed value t of T. This
probability is called the significance level or the P value. If the P value is small,
that is regarded as a sign that there is an effect. What constitutes sufficiently
small should depend on the background of the problem, although it is
customary to use 0.05 or 0.01 as levels to determine statistical significance. If
he chooses a statistic that is not sensitive to deviations from the null hypoth-
esis, he is unlikely to get a low P value even when the hypothesis is false and
there is an effect. So it pays for him to select a statistic and an experimental
design that will be sensitive to those deviations from the null hypothesis in
which he is interested.
Our applications have some unusual aspects. By regarding the question of
whether a gene has an effect on breast cancer, we are effectively testing 18
distinct null hypotheses. In dealing with interactions, we are testing 153 null
hypotheses simultaneously. Our reduced data for the latter problem consists
of two statistics, R and M to be defined below. The methodology is ordinarily
defined for only one test statistic. Our theory is inadequate, in our problem,
to calculate the distribution under the null hypothesis, and thus we have to
resort to randomized permutations. These aspects must be addressed here.
Returning to item 2, Fig. S1 presents, for the 18 genes, estimates of P(V 
t), as estimated by the permutations. The location of the observed value of V
is indicated by a vertical line. The reader will note that none of the 18 P values
represented is significant at the 0.05 level.
3. We seek pairwise interactions among the 18 genes. A definition of
pairwise interactions between two genes is given first. There are a total of 18
 17/2 153 gene pairs. We shall measure the amount of interaction between
two genes, saygi andgj, as follows: For each pair of SNPs, (id, je), one from gene
i and another from gene j, define the SNP-wise interactions as the ratio of
incremental interactions vs. the maximum of the two marginal effects. That is,
rid, je
vidje vid  vje
vid  vje
, [3]
where ‘‘’’ stands for maximum of the two values. This ratio represents the
relative amount of interactions of two SNPs with respect to their marginal
effects. The amount of interactions between two genes i and j is then defined
as the average of all SNP-wise ratios possibly formed from these two genes and
will be denoted by
Rij
d1mi e1mj rid, je
mimj
. [4]
We term this as the ‘‘mean interaction ratio’’ between two genes, or simply,
the Mean-ratio or R statistic. In step 6 below, we will introduce an alternative
Quantile-ratio or Q statistic.
For each gene pair, we also define the ‘‘average maximum marginal v’’ or
‘‘M statistic’’ as
Mij
d1mi e1mj vid  vje
mimj
[5]
4. From steps 1–3 above, we obtained a set of 153 points, {(Mij,Rij); 1  i 
j 18}, corresponding to all possible gene pairs. We use a scatter plot of R vs.
M in Fig. 3, to display these 153 points. The same procedure was repeated on
1,000 permutated datasets. This process will generate 1,000 sets of points,
each set consisting of 153 points, {(Mij
(p), Rij
(p)); 1  I  j  18}  	(p), where p
stands for the pth permutation. It also generates 153 sets consisting of 1,000
points each.
5. Based on these 1,000 sets {	 (p)}, each having 153 points, we construct a
95% confidence curve on the (M, R) plane as shown in Fig. 3 by the dark blue
curve, and as described below. Points above the dark blue curve will represent
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potentially significant gene pairs. This method will be called the Mean-ratio
curve method.
We place all points (total 153  1,000  153,000 points) obtained from
these 1,000 permutations on the (M, R) plane. The values of the M coordinate
are binned into 100 bins, each with 1,530 points. Each bin is represented by a
point with coordinates (M*, R*), where M* is the mid value of the bin, and R*
is the 95th percentile of those R scores falling into the bin. A smoothing fit,
using a spline with 15 knots, is made to the curve formed by these 100 points
(M*,R*), and the resulting dark blue curve is shown in Fig. 3. We also introduce
the following curve method of assigning significance levels. For each gene pair
(i, j), we shall determine its nominal P value by Sij/1,530 when the pair’sR value
is the Sij highest among all 1,530 R values obtained from 1,000 permutations
that fall into the same bin. We use the term ‘‘nominal’’ because this method
does not satisfy the standard criterion of applying the null distribution of a
one-dimensional test statistic. The Rank method to be described later does
satisfy criterion.
6. The ratio measure of interaction is sensitive to the possibility that a
relatively low interaction for two SNPs has a high ratio when both marginal
effects are very small. The resulting high ratio may have a large effect on the
overall mean Rij. Instead of using R  Rij, we moderate this problem by
introducing an alternative measure of interaction between two genes i and j
as the top 90th quantile of the SNP-wise ratios formed by the mimj SNP pairs.
This will be denoted by Q  Qij and will be called the Quantile statistic. With
Rij replaced by Qij, we carried out steps 4 and 5 and obtained 153 points {(Mij,
Qij); 1  i  j  18}. The same procedure was applied to 1,000 permutated
datasets generating 153,000 points. We apply the smoothing techniques
described in step 5 to these points, leading to a dark blue curve shown in Fig.
4. We will call this the Quantile-ratio method.
7. With mild modifications and adequate computational power, the six
steps described above can be generalized to detect third- or higher-order
interactions. For example, in three-way interactions, consider three SNPs as a
triplet, (id, je, kf), each selected from the respective genes i, j, and k. The
three-way-SNP-wise interaction is now defined as the ratio of incremental
interactions vs. the maximum of the three marginal effects. That is,
rid, je, kf
vid jekf vid je  vidkf  vjckf
vid je  vidkf  vjekf
. [6]
At the gene level, we define the three-way interaction with genes i, j, and k
as the average of all three-way SNP-wise ratios formed from these three genes,





Analogously, one can mimic the quantile statistic to calculateQijk for the three
genes i, j, and k.
For each gene triplets, we also define
Mijk
vid je  vidkf  vjekf
mimjmk
. [8]
With the scatter plots of (M, R) and (M, Q) based on a number of permuted
datasets, we can derive the threshold curves to set various significant levels.
Every point of these sets corresponds to a triplet with three genes involved. For
the current data, there are 18  17  16/6  816 such triplets. Instead of the
95-percentile level, we use the 99.5% level to determine R* values in each bin
and the threshold curves (Fig. S4 and Fig. S5).
8. The methods used in steps 5–7, to determine which pairs of genes yield
a significant signal, depend for their power on an implicit assumption that the
1,000 points for one pair of genes gives rise to a similar cloud as for another
pair of genes. Although an informal view supports this assumption, an alter-
native rank procedure is more reliable and more directly in keeping with the
principle of using a single test statistic to evaluate the P value for a given
hypothesis. This method uses the bins of step 5. We have called the first
method the curve method, and this alternative, the rank method.
Consider the gene pair (i, j) and the corresponding statistics (Mij, Rij). From
the permutations we have 1,530 points (M, R) in each of 100 bins. The values
ofR in each bin are ranked from 1 to 1,530. IfRij falls between the permutation
derived points with ranks s
 1 and s in the bin for (i, j), the gene pair is given
the value T  s. For this gene pair, there are 1,000 values of T(p) derived from
the permutations, and the proportion of T(p)  T is the P value for the gene
pair. In effect, the rank method uses the bins for constructing the original
method of finding pairs that are significant at the 5% level as the source of a
one-dimensional statistic from which a traditional P value can be constructed.
The same approach applies to (M, Q). Table 1 displays the respective P values
obtained from the curve and rank procedures for those gene pairs above the
curve in Figs. 3 and 4.
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